IRLA
IRulya Therapeutics Inc.
IRLA | NASDAQ
$34.00
+$1.05 (+3.19%)
Nov 2, 2026, 2:29 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 | Q3 2022 Sep 30, 2022 | Q2 2022 Jun 30, 2022 | Q1 2022 Mar 31, 2022 | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 36K | n/a | n/a | 35K | n/a | 16K | n/a | n/a | n/a | 304K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -36K | n/a | n/a | -35K | n/a | -16K | n/a | n/a | n/a | -304K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -79.78M | -11.11M | -19.35M | -13.43M | -9.9M | -14.86M | -10.11M | -5.86M | -28.19M | -11.22M | -8.34M | -6.09M | -5.58M | -12.96M | -6.32M | -7.62M | -16.26M | -21.86M | -23.54M | -21.68M | -21.78M | -23.31M |
Interest Income | 584K | 160K | 227K | 300K | 311K | 406K | 536K | 683K | 823K | 887K | 1.01M | 959K | 805K | 700K | 536K | 315K | 145K | 72K | 105K | 128K | 160K | 227K |
Pretax Income | -75.41M | 30.57M | -36.31M | -13.49M | -15.98M | -14.98M | -12.45M | -5.48M | -27.69M | -11.12M | -8.84M | -5.35M | -4.89M | -12.5M | -5.53M | -7.92M | -16.85M | -21.64M | -23.4M | -21.71M | -21.75M | -23.09M |
Net Income | -75.49M | 35.91M | -39.46M | -13.44M | -16.05M | -15.03M | -12.46M | -5.49M | -27.73M | -11.15M | -8.89M | -5.35M | -4.89M | -12.25M | -5.53M | -7.92M | -16.56M | -21.64M | -23.4M | -21.71M | -21.75M | -23.09M |
Selling & General & Admin | 16.63M | 4.27M | 3.64M | 3.28M | 3.34M | 4.79M | 4.27M | 3.63M | 4.7M | 4.97M | 4.61M | 4.66M | 4.23M | 3.83M | 3.55M | 4.34M | 9.06M | 9.11M | 8.33M | 7.64M | 7.06M | 6.49M |
Research & Development | 5.46M | 6.85M | 12.6M | 8.08M | 6.55M | 8.15M | 5.83M | 4.92M | 4.15M | 3.7M | 3.43M | 1.43M | 1.35M | 3.23M | 2.77M | 2.45M | 7.2M | 12.76M | 15.21M | 14.04M | 14.72M | 16.82M |
Other Expenses | 57.7M | -36K | 3.12M | 2.07M | -35K | 1.92M | n/a | -2.68M | 19.35M | 2.55M | n/a | n/a | n/a | 5.9M | n/a | 825K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 79.78M | 11.08M | 19.35M | 13.43M | 9.86M | 14.86M | 10.09M | 5.86M | 28.19M | 11.22M | 8.04M | 6.09M | 5.58M | 12.96M | 6.32M | 7.62M | 16.26M | 21.86M | 23.54M | 21.68M | 21.78M | 23.31M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 79.78M | 11.11M | 19.35M | 13.43M | 9.9M | 14.86M | 10.11M | 5.86M | 28.19M | 11.22M | 8.34M | 6.09M | 5.58M | 12.96M | 6.32M | 7.62M | 16.26M | 21.86M | 23.54M | 21.68M | 21.78M | 23.31M |
Income Tax Expense | 75K | -5.34M | 3.15M | -46K | 67K | 47K | 7K | 13K | 36K | 31K | 51K | n/a | n/a | -248K | n/a | n/a | -284K | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.13M | 250.49K | 250.49K | 269.76K | 233.43K | 219.71K | 216.31K | 215.82K | 215.48K | 215.05K | 204.87K | 180.37K | 179.59K | 179.28K | 180.68K | 178.06K | 162.34K | 150.67K | 148.84K | 148.84K | 147.94K | 147.78K |
Shares Outstanding (Diluted) | 6.13M | 250.49K | 250.49K | 269.76K | 233.43K | 219.71K | 216.31K | 215.82K | 215.48K | 215.05K | 204.87K | 180.37K | 179.59K | 179.28K | 180.68K | 178.06K | 162.34K | 150.67K | 148.84K | 148.84K | 147.94K | 147.78K |
EPS (Basic) | -12.31 | 143.40 | -150 | -50 | -68 | -68 | -56 | -26 | -128 | -52 | -44 | -30 | -28 | -68 | -32 | -46 | -102 | -142 | -158 | -146 | -148 | -156 |
EPS (Diluted) | -12.31 | 143.40 | -150 | -50 | -68 | -68 | -56 | -26 | -128 | -52 | -44 | -30 | -28 | -68 | -32 | -46 | -102 | -142 | -158 | -146 | -148 | -156 |
EBITDA | -75.37M | 30.61M | -16.2M | -11.33M | -15.95M | -12.9M | -12.44M | -8.46M | -8.8M | -8.63M | -8.54M | -5.35M | -4.89M | -7.04M | -5.49M | -6.76M | -16.76M | -21.6M | -23.32M | -21.62M | -21.67M | -23.23M |
EBIT | -75.41M | 30.57M | -16.24M | -11.36M | -15.98M | -12.93M | -12.45M | -8.55M | -8.84M | -8.67M | -8.84M | -5.35M | -4.89M | -7.06M | -5.53M | -6.8M | -16.85M | -21.64M | -23.4M | -21.71M | -21.75M | -23.31M |
Depreciation & Amortization | 41K | 36K | 39K | 36K | 35K | 32K | 16K | 86K | 44K | 40K | 304K | n/a | 1K | 17K | 42K | 40K | 84K | 38K | 84K | 87K | 87K | 86K |
Add to Watchlist
Select watchlists to add or remove IRLA